title: Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.
abstract: OBJECTIVE
  There is increasing data suggesting that African Americans with NAFLD tend to have less progressive liver disease. The aim of this study is to assess differences in the hepatic gene expression of African-American and Caucasian patients with NAFLD who had undergone bariatric surgery.
  
  
  METHODS
  A total of 94 patients (81 NAFLD and 13 weight-matched controls with normal liver biopsy) were included. Of the entire cohort, 73 were Caucasians and 21 were African Americans. All patients were undergoing bariatric surgery. Two liver biopsies were obtained at the time of surgery. One biopsy was snap-frozen for gene expression and the other biopsy was stained for pathologic assessment. Liver biopsy confirmed that 24 patients from our cohort had NASH while 57 had only simple steatosis. Snap-frozen liver biopsy specimens of these patients were then used for the RNA extraction. cDNA probes were hybridized with customized microarray gene chips containing 5,220 relevant genes. Gene expression profiles were compared between groups using significance analysis of microarrays algorithm.
  
  
  RESULTS
  In comparison to all Caucasian patients, African-American patients had over-expression of EPB41L1, IGF2, FAH, ACSL4, FUT4, CYP3A (q values < 10(-4)). In comparison to Caucasian NAFLD patients, African-American NAFLD patients showed over-expression of EPB41L1 and ACSL4 genes. Finally, in comparison to Caucasian NASH patients, African-American NASH patients showed over-expression of GSTM 2, GSTM4 and GSTM5 as well as FH and ASCL4 genes. Some genes highlighted by this analysis, particularly cytochrome CYP3A and glutathione transferases GSTM2, 4, 5, were previously implicated in the pathogenesis of NASH.
  
  
  CONCLUSIONS
  African-American patients with biopsy-proven obesity-related NAFLD and NASH have a specific hepatic gene expression pattern that may explain their differences from Caucasian patients with NAFLD in developing progressive liver disease.
authors.affiliation: Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Stepanova
authors.forename: Noreen
authors.initials: N
authors.lastname: Hossain
authors.forename: Arian
authors.initials: A
authors.lastname: Afendy
authors.forename: Kellie
authors.initials: K
authors.lastname: Perry
authors.forename: Zachary D
authors.initials: ZD
authors.lastname: Goodman
authors.forename: Ancha
authors.initials: A
authors.lastname: Baranova
authors.forename: Zobair
authors.initials: Z
authors.lastname: Younossi
mesh_terms: D000328:Adult; D001741:Black or African American / Q000235:genetics*; D001706:Biopsy; D001774:Blood Chemical Analysis; D005227:Fatty Acids / Q000235:genetics; D005234:Fatty Liver / Q000208:ethnology / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D009767:Obesity, Morbid / Q000150:complications* / Q000601:surgery; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D018384:Oxidative Stress / Q000235:genetics; D044465:White People / Q000235:genetics*
chemical_list: D005227:Fatty Acids